Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dennis Duncan

Physician Assistant, Medical Roanoke, VA Physician Assistant

NPI 1417229816 CMS profile 11140447

3390 Colonial Ave, Roanoke, VA 24018

Open in the dashboard

General payments

$7,797

478 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dennis Duncan of Roanoke, VA is reported in the CMS Open Payments database as having received $7,797 across 478 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $682 39
2024 General $1,203 68
2023 General $1,576 81
2022 General $2,028 127
2021 General $2,308 163

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Duncan
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Dennis Duncan were reported at $682. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Dennis Duncan Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,308 $156 $41–$563 $132
2022 $2,028 $185 $55–$649 $149
2023 $1,576 $199 $58–$717 $160
2024 $1,203 $206 $62–$740 $164
2025 $682 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,106 102 payments
  2. Novo Nordisk Inc $875 43 payments
  3. AstraZeneca Pharmaceuticals LP $655 34 payments
  4. Amgen Inc. $631 38 payments
  5. Esperion Therapeutics, Inc. $437 24 payments
  6. Janssen Pharmaceuticals, Inc $313 26 payments
  7. GlaxoSmithKline, LLC. $305 18 payments
  8. Lilly USA, LLC $259 15 payments
  9. Pfizer Inc. $254 17 payments
  10. Otsuka America Pharmaceutical, Inc. $235 13 payments
  11. Other $2,727 148 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,788 477 payments
  2. Education $8 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $844 41 payments
  2. RYBELSUS $707 38 payments
  3. FARXIGA $462 21 payments
  4. NEXLETOL $437 24 payments
  5. UBRELVY $416 37 payments
  6. VRAYLAR $393 36 payments
  7. Otezla $347 24 payments
  8. Repatha $339 19 payments
  9. BREZTRI $289 9 payments
  10. NURTEC ODT $288 13 payments
  11. Other $5,837 365 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

3,003

Median for Physician Assistant: 241

Drug cost

$87,479

Median for Physician Assistant: $4,110

Branded share of claims

12.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 18 $19,252
Eliquis Apixaban Brand 23 $15,651
Jardiance Empagliflozin Brand 15 $14,220
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $9,355
Gabapentin Generic 129 $2,002
Albuterol Sulfate Hfa Albuterol Sulfate Brand 57 $1,603
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 80 $1,331
Celecoxib Generic 15 $1,214
Omeprazole Generic 95 $1,124
Levothyroxine Sodium Generic 85 $1,108

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $83
  • Lundbeck LLC $26
$109 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $81
$81 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $44
  • Lilly USA, LLC $36
$80 15 —
VRAYLAR
  • AbbVie, Inc. $72
$72 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

478 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record